Unexpected Response to Hormonal Therapy in Metastatic Neuroendocrine-Differentiated Prostate Adenocarcinoma: A Case Report.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
consolidation chemotherapy and remains in complete and durable remission, with an undetectable PSA level
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This case illustrates that significant sensitivity to ADT can persist even in the context of aggressive prostate cancer with neuroendocrine features and acute organ dysfunction. It challenges the routine exclusion of hormonal therapy in such scenarios and highlights the potential of ADT as a life-saving therapeutic bridge in critical clinical settings.
Prostate cancer with neuroendocrine differentiation (NEPC) is an aggressive subtype typically considered androgen-indifferent and primarily managed with chemotherapy.
APA
Maadin K, Alem M, et al. (2025). Unexpected Response to Hormonal Therapy in Metastatic Neuroendocrine-Differentiated Prostate Adenocarcinoma: A Case Report.. Cureus, 17(9), e91967. https://doi.org/10.7759/cureus.91967
MLA
Maadin K, et al.. "Unexpected Response to Hormonal Therapy in Metastatic Neuroendocrine-Differentiated Prostate Adenocarcinoma: A Case Report.." Cureus, vol. 17, no. 9, 2025, pp. e91967.
PMID
40949061 ↗
Abstract 한글 요약
Prostate cancer with neuroendocrine differentiation (NEPC) is an aggressive subtype typically considered androgen-indifferent and primarily managed with chemotherapy. Presentation as a hepatic visceral crisis constitutes a medical emergency with high mortality, often requiring urgent systemic chemotherapy. We report the case of a 52-year-old male patient who presented with life-threatening hepatic visceral crisis as the initial manifestation of metastatic neuroendocrine differentiated prostate adenocarcinoma, Gleason score 9 (4 + 5), with a prostate-specific antigen (PSA) level of 137 ng/mL. Remarkably, first-line androgen deprivation therapy (ADT) as monotherapy led to rapid and marked clinical improvement, with complete normalization of liver function tests within one month, prior to any chemotherapy. The patient subsequently underwent consolidation chemotherapy and remains in complete and durable remission, with an undetectable PSA level. This case illustrates that significant sensitivity to ADT can persist even in the context of aggressive prostate cancer with neuroendocrine features and acute organ dysfunction. It challenges the routine exclusion of hormonal therapy in such scenarios and highlights the potential of ADT as a life-saving therapeutic bridge in critical clinical settings.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.
- Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration-Sensitive Prostate Cancer.
- Impact of androgen deprivation therapy on sexual health in patients who underwent brachytherapy for prostate cancer.
- PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.
- GSTA1 deficiency drives neuroendocrine differentiation via TNFRSF13B/c-FOS/CHGA axis in prostate cancer.